Reseasrch programme: psychiatric disorder therapies - AbbVie/Gilgamesh Pharmaceuticals
Latest Information Update: 29 May 2024
At a glance
- Originator Gilgamesh Pharmaceuticals
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Psychiatric disorders